Teladoc Health Inc. (TDOC) experienced a 5% plummet in its stock price during Friday's pre-market session, adding to the substantial decline it witnessed a day earlier following the release of a scathing short-seller report from Blue Orca Capital.
The report alleged that Teladoc misled investors about its BetterHelp platform, claiming that the company used AI-generated responses in place of licensed therapists without proper disclosures. Additionally, the report accused Teladoc of inflating profitability by shifting research and development expenses.
These allegations have raised concerns among investors about Teladoc's financial reporting and business practices, overshadowing the company's recent acquisition of Catapult Health for $65 million to expand its preventive healthcare offerings. Analysts have also released mixed projections for Teladoc's upcoming quarterly earnings report, with estimates ranging from a 23.5% year-over-year decline in earnings per share to modest revenue growth in certain segments.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。